Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data

Odyssey Therapeutics, Inc.

Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.
Net loss of $38.3M for Q1 2026, comparable to $38.4M in Q1 2025.
R&D expenses $32.3M (down $6.5M YoY); G&A $7.4M (down $0.6M YoY).
Phase 2a proof-of-concept for OD-001: 27% clinical remission, 61% clinical response in UC.
Plan to launch Phase 2b monotherapy and Phase 2a combo trial with vedolizumab in H2 2026; data H2 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Odyssey Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income $38.3 million.

Period: the three months ended March 31, 2026
Net income: $38.3 million
Result: reported results

Exact text from the filing

Net loss was $38.3 million for the quarter ended March 31, 2026, compared to a net loss of $38.4 million for the same period in 2025.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Odyssey Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-274291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.